Product Description
Mechanisms of Action: GABA Partial Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alzheon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Alzheimer Disease|Cerebral Amyloid Angiopathy
Phase 2: Cerebral Hemorrhage|Cerebral Amyloid Angiopathy, Familial|Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2006-006490-24 | P3 |
Completed |
Alzheimer Disease |
2010-04-19 |
|
| 2004-003435-31 | P3 |
Completed |
Cerebral Amyloid Angiopathy|Alzheimer Disease |
2007-12-14 |
|
| CL-758003 | P2 |
Completed |
Cerebral Hemorrhage|Cerebral Amyloid Angiopathy, Familial|Stroke |
None |
|
| CL-758017 | P3 |
Unknown status |
Alzheimer Disease |
None |